Navigation Links
Esophageal Cancer Patients' Positive Responses to Chemotherapy Accurately Identified by PET

WASHINGTON, D.C. At the 54th Annual Meeting of SNM, the world's largest society for molecular imaging and nuclear medicine professionals, German researchers stated that early metabolic imaging with positron emission tomography (PET), accurately identifies patients responding to chemotherapy for esophageal cancer.

"This is the first study to apply PET results from early metabolic response assessment to clinical decision making in the treatment of common solid tumors," said Ken Herrmann, a resident in the department of nuclear medicine at Technical University in Munich, Germany.

"The outcome for metabolic responders turned out to be remarkably favorable compared to metabolic non-responders. Our results show that PET helps select patients who are benefiting from chemotherapy," he noted. "Based on our early response assessment, the course is set for tailoring multimodality treatment on the basis of tumor biology," explained Herrmann.

In addition, PET-response-guided treatment "helped circumvent the administration of inefficient chemotherapy to patients with no metabolic responsewithout compromising their outcome," added Herrmann.

Less well-known than lung cancerbut no less seriousesophageal cancer starts in the inner layer of the esophagus, the 10-inch long tube that connects your throat and stomach. Adenocarcinoma is esophageal cancer that begins in cells that make and release mucus and other fluids. In this country, more than 14,000 persons are expected to die from the disease, and more than 15,000 new cases will be diagnosed this year.

The MUNICON trial, conducted from May 2003 through August 2005, was the first study conducted to apply PET results from early metabolic response assessment to clinical decision-making in the treatment of common solid tumors, said Herrmann. "This clinical trial delineated how response-guided treatment algorithms may be applied to clinical practice, serving as a model for other malignant diseaseslike lung, head and neck or ovarian cancerand providing information to alter treatment and patient management," he explained. "The results of our study delineate how response-guided treatment algorithms can be applied in clinical practice in the future," said Herrmann.

PET is a powerful medical imaging procedure that noninvasively demonstrates the function of organs and tissues. When PET is used to image cancer, a radiopharmaceutical (such as fluorodeoxyglucose or FDG, which which is a radioactive analog of sugar) is injected into the vein of a patient. Cancer cells metabolize sugar at higher rates than normal cells, and the radiopharmaceutical is taken up in higher concentrations to cancerous areas.

PET scans show where FDG is by tracking photons given off by the radioactive tracer. PET scanning provides information at a molecular levelnot available through other proceduresabout the body's chemistry, metabolic activity and body function.


'"/>




Related medicine news :

1. Soft Drinks May Reduce Esophageal Cancer Risk
2. PET Can Predict Response To Treatment In Esophageal Cancer Patients
3. Hiccups May Be An Indication Of Esophageal Cancer
4. Test for Esophageal Reflux Licensed to Bayer by University
5. Studies Find Connection Between Acid Reflux And Esophageal Cancer
6. Rise in Esophageal Cancer is emphasized by Richards’ deat
7. Esophageal Cancer Rates Climb With Obesity
8. New Wireless System Developed to Detect Esophageal Reflux
9. Fibroids unlikely to Turn Cancerous
10. Virus Level could Predict Cervical Cancer Risk
11. Cancer Doctors Okays Controversial Prostate Therapy
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: